Diagnosis and treatment of focal-segmental glomerulosclerosis-2023
© 2023. The Author(s)..
The histopathological term focal-segmental glomerulosclerosis comprises different pathogenic processes with the unifying features of a high proteinuria and the name-giving glomerular lesion pattern seen on light microscopy. A differentiation according to the underlying cause into primary, secondary and genetic forms is therefore of utmost importance. The pathogenesis of primary focal-segmental glomerulosclerosis remains unknown but, like minimal-change disease, an autoimmune-mediated process leading to podocyte damage is assumed. Consequently, the unifying term "podocytopathy" is increasingly being used for both entities. Supportive treatment measures to preserve kidney function are important in all subtypes. In contrast, immunosuppressive treatment is only indicated in primary focal-segmental glomerulosclerosis. Steroid-dependence, steroid-resistance and frequently relapsing disease often complicate disease management and necessitate alternative treatment strategies. Here, the Austrian Society of Nephrology (ÖGN) provides consensus recommendations on how to best diagnose and manage patients with focal-segmental glomerulosclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
Wiener klinische Wochenschrift - 135(2023), Suppl 5 vom: 01. Aug., Seite 638-647 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Diagnostik und Therapie der Fokal-Segmentalen Glomerulosklerose – 2023 |
|---|
| Beteiligte Personen: |
Gauckler, Philipp [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
English Abstract |
|---|
| Anmerkungen: |
Date Completed 21.09.2023 Date Revised 23.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00508-023-02260-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362254516 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362254516 | ||
| 003 | DE-627 | ||
| 005 | 20231226090845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00508-023-02260-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362254516 | ||
| 035 | |a (NLM)37728649 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Gauckler, Philipp |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and treatment of focal-segmental glomerulosclerosis-2023 |
| 246 | 3 | 3 | |a Diagnostik und Therapie der Fokal-Segmentalen Glomerulosklerose – 2023 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.09.2023 | ||
| 500 | |a Date Revised 23.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a The histopathological term focal-segmental glomerulosclerosis comprises different pathogenic processes with the unifying features of a high proteinuria and the name-giving glomerular lesion pattern seen on light microscopy. A differentiation according to the underlying cause into primary, secondary and genetic forms is therefore of utmost importance. The pathogenesis of primary focal-segmental glomerulosclerosis remains unknown but, like minimal-change disease, an autoimmune-mediated process leading to podocyte damage is assumed. Consequently, the unifying term "podocytopathy" is increasingly being used for both entities. Supportive treatment measures to preserve kidney function are important in all subtypes. In contrast, immunosuppressive treatment is only indicated in primary focal-segmental glomerulosclerosis. Steroid-dependence, steroid-resistance and frequently relapsing disease often complicate disease management and necessitate alternative treatment strategies. Here, the Austrian Society of Nephrology (ÖGN) provides consensus recommendations on how to best diagnose and manage patients with focal-segmental glomerulosclerosis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Focal-segmental glomerulosclerosis | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Podocytopathy | |
| 650 | 4 | |a Proteinuria | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Supportive therapy | |
| 700 | 1 | |a Zitt, Emanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Regele, Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Eller, Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Säemann, Marcus D |e verfasserin |4 aut | |
| 700 | 1 | |a Lhotta, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Neumann, Irmgard |e verfasserin |4 aut | |
| 700 | 1 | |a Rudnicki, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Odler, Balazs |e verfasserin |4 aut | |
| 700 | 1 | |a Kronbichler, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Zschocke, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Windpessl, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d 1946 |g 135(2023), Suppl 5 vom: 01. Aug., Seite 638-647 |w (DE-627)NLM000045071 |x 1613-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2023 |g number:Suppl 5 |g day:01 |g month:08 |g pages:638-647 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00508-023-02260-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2023 |e Suppl 5 |b 01 |c 08 |h 638-647 | ||